Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients

Aims The GLP1 agonist lixisenatide is glucagonostatic and reduces post‐prandial blood glucose (PPBG) in type 2 diabetes. This study investigates its impact in type 1 diabetes (T1D). <br></br> Methods In a blinded, crossover trial, 25 patients with T1D were randomised to 4 weeks adjunctiv...

Descrición completa

Detalles Bibliográficos
Main Authors:	Ballav, C, Dhere, A, Kennedy, I, Agbaje, O, Owen, K, White, S, Franklin, R, Hartman, B, Holst, J, Holman, J
Formato:	Journal article
Idioma:	English
Publicado:	Wiley 2020

Títulos similares

Economic analysis of Lixisenatide in Diabetes Mellitus Type 2
por: A. S. Kolbin, et al.
Publicado: (2018-05-01)

Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2
por: S. V. Nedogoda, et al.
Publicado: (2020-01-01)

The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus
por: I. N. Dyakov, et al.
Publicado: (2021-02-01)

Health technology assessement of the fxed combination of insulin glargine 100 UI/ml and lixisenatide in the treatment intensifcation of diabetes mellitus type 2
por: S. К. Zyryanov, et al.
Publicado: (2019-01-01)

Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U‐100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring
por: Yuji Kawaguchi, et al.
Publicado: (2024-05-01)

Real World Effectiveness of fixed combination of glargine 100 U/ml and lixisenatide therapy in outpatients with Type 2 Diabetes: A Retrospective Cohort Study SOLO
por: M. B. Antsiferov, et al.
Publicado: (2022-05-01)

Pharmacokinetics of Lixisenatide, a GLP-1 Receptor Agonist, Determined by a Novel Liquid Chromatography–Tandem Mass Spectrometry Analysis in Rats
por: Hyeon Seok Oh, et al.
Publicado: (2023-04-01)

Impact of Protein Preload Meals on Postprandial Blood Glucose Excursions in Patients with Type 1 Diabetes Mellitus
por: CAI Yunying, LI Mengge, ZHANG Lun, LI Juan, SU Heng
Publicado: (2023-05-01)

Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies
por: Xia Zhang, et al.
Publicado: (2021-03-01)

Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro)
por: Cornelia Bala, et al.
Publicado: (2022-05-01)

Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world
por: George Dailey, et al.
Publicado: (2019-05-01)

Glucagon, rather than Glucagon-Like Peptide 1, Mediates Higher Post-Lunch Glucose Excursions during Breakfast Skipping in Asian Indian Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Yash V. Chauhan, et al.
Publicado: (2024-12-01)

Real-world effectiveness and safety of fixed-ratio combination insulin glargine 100 u/ml plus lixisenatide in adults with type 2 diabetes (T2DM): subanalysis of the international, multicentre, prospective observational study SUCCESS in the Russian population
por: O. K. Vikulova, et al.
Publicado: (2024-11-01)

Changing Meal Sequence Affects Glucose Excursions in Gestational Diabetes Mellitus
por: Guangjin Yong, et al.
Publicado: (2022-01-01)

Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?
por: Matthias Ploug Larsen, et al.
Publicado: (2017-01-01)

PROLONGED INFUSION OF GLUCAGON-LIKE PEPTIDE-1 IN TYPE-2 DIABETES NORMALIZES INSULIN-RESPONSE TO GLUCOSE
por: Gribble, F, et al.
Publicado: (1995)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
por: Nina A. Petunina, et al.
Publicado: (2018-09-01)

Glucagon like peptide-1 similarly amplifies insulin secretion in late-onset type 1 and type 2 diabetes
por: Maksoud, H, et al.
Publicado: (1999)

Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes
por: Douglas E. James, et al.
Publicado: (2024-07-01)

Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes
por: Kim, A, et al.
Publicado: (2021)

Assessment of Two Different Glucagon Assays in Healthy Individuals and Type 1 and Type 2 Diabetes Patients
por: Martina Brunner, et al.
Publicado: (2022-03-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017-10-01)

Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
por: Ortal Resnick, et al.
Publicado: (2025-01-01)

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
por: Xinrui Tan, et al.
Publicado: (2023-03-01)

Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes
por: Sherman S. Leung, et al.
Publicado: (2023-08-01)

The effect of exogenous glucagon on circulating amino acids in individuals with and without type 2 diabetes and obesity
por: Magnus F G Grøndahl, et al.
Publicado: (2024-02-01)

Type 1 and type 2 diabetes-chalk and cheese?
por: Owen, K, et al.
Publicado: (2009)

Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes.
por: Zhang, Q, et al.
Publicado: (2013)

NON-SULFONYLUREA A4166 STIMULATES INSULIN IN TYPE-2 DIABETES AND REDUCES POSTPRANDIAL GLUCOSE EXCURSION BY 64-PERCENT
por: Levy, J, et al.
Publicado: (1995)

Risk of microvascular complications over 30 years in latent autoimmune diabetes of adults compared with type 2 diabetes
por: Maddaloni, E, et al.
Publicado: (2019)

Glucagon: Physiological and Pharmacological Functions and Pathophysiological Significance in Type 2 Diabetes
por: Tadahiro Kitamura
Publicado: (2024-02-01)

Continuous glucose monitoring guides glucagon-like peptide 1-based therapy use and optimization in people with type 2 diabetes
por: Rita Parsiani, et al.
Publicado: (2025-02-01)

Modern types of excursion activities
por: Olesia Dolynska, et al.
Publicado: (2024-09-01)

Glycemic Excursions in Type 1 Diabetes in Pregnancy: A Semiparametric Statistical Approach to Identify Sensitive Time Points during Gestation
por: Resmi Gupta, et al.
Publicado: (2017-01-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
por: Ekaterina V. Tikhonenko, et al.
Publicado: (2018-12-01)

Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
por: Alina Yu. Babenko, et al.
Publicado: (2019-01-01)

Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Xie Z, et al.
Publicado: (2024-04-01)

Myricetin Increases Circulating Adropin Level after Activation of Glucagon-like Peptide 1 (GLP-1) Receptor in Type-1 Diabetic Rats
por: Ying-Xiao Li, et al.
Publicado: (2022-01-01)

Variable glucagon metabolic actions in diverse mouse models of obesity and type 2 diabetes
por: Yuqin Wu, et al.
Publicado: (2024-12-01)

Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic β-Cell Regeneration In Situ in Type 1 Diabetic Mice
por: Liangbiao Gu, et al.
Publicado: (2021-01-01)